Agoraphobia Market Size, Growth, Trends, Forecast 2030

Q: Name the notable players of the global agoraphobia market?

Eli Lilly &amp; Co., AstraZeneca, Bristol-Myers Squibb, Apotex Corp., Johnson &amp; Johnson, Pfizer Inc, Sandoz Inc., Mylan Pharmaceuticals Inc., and GlaxoSmithKline plc are major players of the global agoraphobia market.. Read More

Agoraphobia Market Overview

The Agoraphobia market is projected to reach USD 1,682.8 Million by 2030 at 6.9% CAGR during the forecast period 2022-2030.

Agoraphobia Market Overview

Agoraphobia is the fear of places or situations that causes panic behaviour with a feeling of being trapped or helpless. The situation may be actual or anticipated such as using public transportation, being in open or enclosed spaces or being in a crowded place. Signs and symptoms of a panic attack in agoraphobia are rapid heart rate, trouble breathing, chest pain, dizziness, excessive sweating, feeling of loss of control and fear of dying etc. Agoraphobia is primarily caused by a combination of genetic and environmental factors. Other conditions include separation anxiety, posttraumatic stress and depression. Agoraphobia patients are at a higher risk of depression and substance use disorder. Agoraphobia is prevalent in about 1.7% of adults with women having a greater propensity to be affected by the disorder.

The market for agoraphobia diagnosis and treatment is driven by factors such as growing prevalence of stress, genetic predisposition, sedentary lifestyles, deteriorating health standards in the contemporary lifestyles, substance abuse, lack of intimacy in relations, increasing awareness and screening etc. The agoraphobia market restraints are social stigma regarding psychotherapy, low focus and penetration of mental health in society, tendency to hide mental disorders and reluctance to therapy and treatment etc.

Cognitive behavioural therapy is the leading psychotherapy for agoraphobia. Cognitive behavioural therapy focuses on teaching skills to better tolerate anxiety, challenging your worries and anticipating most probable and realistic effects of the situation or place. Exposure therapy focus on increasing exposure to places which trigger a panic attack and to cope and tolerate symptoms of agoraphobia. Desensitization caused by exposure therapy results in habituation which improves the condition.

The therapist helps the patient to understand thought patterns and false beliefs or attitudes which raises anxiety with an aim to change ways of thinking and to make thought patterns more realistic and helpful. Selective serotonin reuptake inhibitors such as fluoxetine and sertraline are the standard drug therapy for the treatment of panic disorder in agoraphobia. Anti-anxiety drugs called benzodiazepines are used as or to relieve acute anxiety as they are habit-forming. Dietary supplements and alternative medicines such as kava kava have been tried and have found to be useful. However, kava kava has been reports of serious liver damage. The Food and Drug Administration has issued warnings and thus kava kava should be avoided if liver problems exists.

Figure 1 Global Agoraphobia market by Surgery, 2016 (% Market Share)

Agoraphobia Market Share

Agoraphobia Market Segmentation

The global agoraphobia market is segmented on the basis of drug treatment, therapy and end users.

Based on drug treatment, the agoraphobia market has been segmented as selective serotonin reuptake inhibitors, norepinephrine reuptake inhibitors, tricyclic antidepressants, anti-anxiety medications and others.

Based on the therapy, the market has been segmented as psychotherapy, cognitive behavioral therapy (CBT), exposure therapy and others. Based on the end users, the market has been segmented as hospitals, clinics, academics and others.

Agoraphobia Market Regional Analysis

US accounts for the maximum market share due to favorable insurance penetration, excellent reimbursement scenario and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the market for global agoraphobia diagnosis and treatment. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region agoraphobia market is expected to have the most future potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.

Key Players of Global Agoraphobia Market

Key players profiled in the agoraphobia market report are:

Eli Lilly & Co.,

Bristol-Myers Squibb,

AstraZeneca,

Pfizer inc,

GlaxoSmithKline plc,

Johnson & Johnson,

Sandoz Inc.,

Apotex Corp.,

Mylan Pharmaceuticals Inc.

The report for Global agoraphobia market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different agoraphobia market segments and regions.

Intended Audience

Global Agoraphobia diagnosis and treatment solutions, manufacturers & suppliers

Research and development (R&D) companies

Hospitals and clinics

Academic institutes and universities

Agoraphobia Market Outlook

Sources: Mayo Clinic, MRFR Analysis.

Report Attribute/Metric	Details
Market Size	2030: USD 1,682.8 Million
CAGR	2022-2030: ~ 6.9%
Base Year	2021
Forecast Period	2022-2030
Historical Data	2020
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Drug treatment, Therapy and End users
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Eli Lilly & Co., Bristol-Myers Squibb, AstraZeneca, Pfizer inc, GlaxoSmithKline plc, Johnson & Johnson, Sandoz Inc., Apotex Corp., Mylan Pharmaceuticals Inc
Key Market Opportunities	Faster market uptake of new technology and devices in the US US accounts for the maximum market share due to favorable insurance penetration, excellent reimbursement scenario and greater expenditure on healthcare.
Key Market Drivers	Growing prevalence of stress, genetic predisposition Sedentary lifestyles Deteriorating health standards in the contemporary lifestyles Increasing awareness and screening etc

Agoraphobia Market Highlights:

Frequently Asked Questions (FAQ) :

What is the valuation of the global agoraphobia market?

agoraphobia market is touted to touch USD 1,682.8 Million by 2030.

What is the expected growth rate of the global agoraphobia market?

agoraphobia market is expected to register 6.9% from 2022 to 2030.

Which region has the largest market share in the global agoraphobia market?

The U.S. has the largest market share in the global agoraphobia market due to insurance schemes and favorable reimbursement schemes.

Which region has the largest potential in the global agoraphobia market?

The APAC region has the largest potential in the global agoraphobia market.

Name the notable players of the global agoraphobia market?

Eli Lilly & Co., AstraZeneca, Bristol-Myers Squibb, Apotex Corp., Johnson & Johnson, Pfizer Inc, Sandoz Inc., Mylan Pharmaceuticals Inc., and GlaxoSmithKline plc are major players of the global agoraphobia market.

Leading companies partner with us for data-driven Insights.

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

FEATURES	LICENCE TYPE
FEATURES	Single User	Multiuser Licence	Enterprise User
Price	$ 4,950	$ 5,950	$ 7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout The Organization.
Free Customization
Direct access to the Analyst
Deliverable Format
Deliverable Format
Platform Access
Discount on Your Next Purchase	10%	15%	10%
Printable Versions

Agoraphobia Market Information by drug treatment (selective serotonin reuptake inhibitors, norepinephrine reuptake inhibitors, others) by therapy (Psychotherapy, Cognitive Behavioral Therapy (CBT), others) by end users - Forecast till 2030

Agoraphobia Market Overview

Agoraphobia Market Segmentation

Agoraphobia Market Regional Analysis

Key Players of Global Agoraphobia Market